Interestingly, it has been shown that constitutively active AR splice variants (AR-Vs)—a well-described resistance mechanism in prostate cancer—are present in a large subset of breast cancer tumors, and that treatment of MDA-MB-453 cells (ER/PR-negative, HER2-negative, AR-positive) with enzalutamide can lead to the induction of AR-Vs [75]. This evidence concerns the gene AR and prostate cancer.